EyePoint Pharma to Present at Goldman Sachs 45th Annual Healthcare Conference

June 05, 2024 – EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for serious retinal diseases, announced that its President and CEO, Jay S. Duker, M.D., will present at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference. The presentation is scheduled for Wednesday, June 12, 2024, at 3:20 p.m. ET. Interested parties can access a live webcast of the presentation through the Investors section of EyePoint’s website. An archived replay will be available for 90 days following the event.

EyePoint Pharmaceuticals specializes in innovative treatments for retinal diseases using its proprietary bioerodible Durasert E™ technology. This technology facilitates sustained intraocular drug delivery, representing a significant advancement in treatment options for patients. The company’s leading product candidate, DURAVYU (formerly EYP-1901), is an investigational therapy designed for VEGF-mediated retinal diseases. It combines vorolanib, a patented tyrosine kinase inhibitor, with the Durasert E™ delivery system to offer sustained treatment effects.

The company’s pipeline also includes EYP-2301, a promising TIE-2 agonist, and razuprotafib, both formulated in Durasert E™ to potentially enhance treatment outcomes for retinal conditions. The proven Durasert® technology has been safely used in thousands of patients through four FDA-approved products.

EyePoint Pharmaceuticals operates from its headquarters in Watertown, Massachusetts. The company has an exclusive license for vorolanib from Equinox Sciences, affiliated with Betta Pharmaceuticals, for use in ophthalmic diseases outside of China, Macao, Hong Kong, and Taiwan. It’s important to note that DURAVYU is an investigational product and has not yet received FDA approval, with the timeline for approval remaining uncertain.

The company remains dedicated to pioneering treatments that significantly improve the lives of patients with serious retinal diseases, leveraging advanced drug delivery technologies to provide sustained therapeutic effects.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!